Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs
Running, not enrolling · Phase 2
Conditions studied: Gastroenteropancreatic Neuroendocrine Tumors, Pheochromocytoma, Paraganglioma
In brief
This is a multicenter, open-label, single-arm study to evaluate the safety and dosimetry of Lutathera in adolescent patients 12 to \<18 years old with somatostatin receptor positive GEP-NETs and PPGLs. The study will enroll at least 8 patients in the GEP-NET cohort and as many adolescents with PPGL as possible in the exploratory PPGL cohort.
Key facts
- Study ID
- NCT04711135
- Run by
- Advanced Accelerator Applications
- People needed
- 11
- Starts
- 2022-08-31
- Expected to finish
- 2034-02-06
- Last updated by the study team
- 2026-02-12
Who can join
Age: 12 and older, up to 17. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of Kentucky — Lexington, Kentucky, United States
- Cincinnati Children's Hospital — Cincinnati, Ohio, United States
- Children's Hospital of Philadelphia — Philadelphia, Pennsylvania, United States
- Centre Léon Berard — Lyon, France
- Maria Sklodowska-Curie National Research Institute of Oncology — Gliwice, Poland
- Hospital Universitari Vall d'Hebron — Barcelona, Spain
- University College Hospital of London — London, United Kingdom
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.